Oncopeptides Balance Sheet Health
Financial Health criteria checks 5/6
Oncopeptides has a total shareholder equity of SEK135.7M and total debt of SEK117.2M, which brings its debt-to-equity ratio to 86.4%. Its total assets and total liabilities are SEK319.2M and SEK183.6M respectively.
Key information
86.4%
Debt to equity ratio
SEK 117.16m
Debt
| Interest coverage ratio | n/a |
| Cash | SEK 250.01m |
| Equity | SEK 135.66m |
| Total liabilities | SEK 183.55m |
| Total assets | SEK 319.21m |
Recent financial health updates
Oncopeptides (STO:ONCO) Will Have To Spend Its Cash Wisely
Feb 29
Oncopeptides (STO:ONCO) Has Debt But No Earnings; Should You Worry?
Nov 14We Think Oncopeptides (STO:ONCO) Needs To Drive Business Growth Carefully
Jul 26Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?
Mar 25Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?
Nov 23Recent updates
An Intrinsic Calculation For Oncopeptides AB (publ) (STO:ONCO) Suggests It's 45% Undervalued
Jun 18Oncopeptides (STO:ONCO) Will Have To Spend Its Cash Wisely
Feb 29Oncopeptides (STO:ONCO) Has Debt But No Earnings; Should You Worry?
Nov 14We Think Oncopeptides (STO:ONCO) Needs To Drive Business Growth Carefully
Jul 26Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?
Mar 25Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?
Nov 23Financial Position Analysis
Short Term Liabilities: ONCO's short term assets (SEK289.3M) exceed its short term liabilities (SEK46.3M).
Long Term Liabilities: ONCO's short term assets (SEK289.3M) exceed its long term liabilities (SEK137.3M).
Debt to Equity History and Analysis
Debt Level: ONCO has more cash than its total debt.
Reducing Debt: ONCO's debt to equity ratio has increased from 0% to 86.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ONCO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ONCO has sufficient cash runway for 2.9 years if free cash flow continues to grow at historical rates of 7.9% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 12:10 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Oncopeptides AB (publ) is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Erik Hultgård | Carnegie Investment Bank AB |
| Patrik Ling | DNB Markets |
| Robert Burns | H.C. Wainwright & Co. |